Amivantamab was also evaluated in combination with Lazertinib in 45 chemotherapy naïve NSCLC patients with EGFR mutation (exon 19 deletion or L858R mutation) upon progression to osimertinib: ORR was obtained in 36% of patients (95% CI, 22–51%), with a median progression free survival (PFS) of 4.9 months (95% CI, 3.7–9.7), and it was associated to a manageable toxicity profile [47]. Here, EGFR is linked to non-small cell lung carcinoma.